NewsBenzingaBarclays mantiene la recomendación de sobreponderar a Medline y eleva el precio objetivo a 45 dólares Barclays mantiene la recomendación de sobreponderar a Medline y eleva el precio objetivo a 45 dólares Benzinga 2026.11.20 15:14 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on California Resources, Raises Price Target to $77 B. Riley Securities Reiterates Buy on Orchestra BioMed Hldgs, Raises Price Target to $12 Wells Fargo Maintains Overweight on Crescent Energy, Raises Price Target to $22 Wells Fargo Maintains Overweight on Valvoline, Raises Price Target to $42 Moog Targets Nearly $5 Billion in FY2027 Sales on Strong Defense, Data Center Demand B. Riley Securities Maintains Buy on NioCorp Developments, Lowers Price Target to $8